Diabetes Day for Primary Care Providers

Newark, NJ

Vertical Tabs

Overview

With an aging population and longer life expectancy come an increased prevalence of chronic diseases and conditions, including diabetes. The percentage of United States adults with diabetes (including both diagnosed and undiagnosed) is at least 8.3% (based on 2010 numbers), far exceeding the capacity of the specialists, the endocrinologists, to manage these patients. For example, each year there are more than 28 million ambulatory care visits with diabetes as primary diagnosis.

The vast majority of patients with type 2 diabetes are managed in the primary care setting. Primary care clinicians need to accept the challenge to more aggressively treat their patients with diabetes.  This can help patients reach optimal glycemic goals, reduce the burden of the disease, and improve the patient’s health outcomes and quality of life. As the recognized experts on this metabolic condition, endocrinologists are the content experts and lead authorities in diabetes clinical research and its application to clinical practice. Therefore, they are uniquely qualified to provide continuing education regarding diabetes and its care to primary care physicians.

More effective education for primary care physicians and clinicians can help improve cardiometabolic control in patients with diabetes. With more knowledge, primary care physicians can more effectively educate their patients about the disease and the value of preventive therapy. Awareness of barriers, identification of strategies to overcome obstacles, and further opportunities for practitioners to problem-solve strategies to assist patients in managing a chronic illness that requires numerous daily decisions are all needed.

The program will comprehensively address the complex challenges faced by primary care providers in the areas of diabetes prevention, diagnosis, and treatment, as well as co-morbid conditions that make diabetes such a complex disease. The education will provide an in-depth look at current guidelines, clinical thinking, and management practices to successfully treat diabetes and modifiable cardiometabolic issues. An ethnically and clinically-diverse patient population will also be used to develop interactive “real patient-case” vignettes to help learners better understand the real-world challenges and cultural health disparities of patients with diabetes, as well as how to best address their care.

 

Target Audience

Primary care providers including MDs, DOs, NPs, PAs, RNs, CDEs, Pharmacists and other interested health care providers.

Agenda

Saturday, December 14, 2013

7:00 am - 1:00 pm EST

Diabetes Day for Primary Care Providers

  

Time            Agenda Item
7:00am - 8:00am   Registration & Continental Breakfast
8:00am - 8:10am   Welcome Remarks & Program Overview
8:10am - 8:35am   The Epidemic of Obesity and Type 2 Diabetes
8:35am - 8:45am   Q&A
8:45am - 9:15am   New Paradigm in the Management of Type 2 Diabetes
9:15am - 9:25am   Q&A
9:25am - 9:50am   Where Do GLP-1 Receptor Agonists and DPP4 Inhibitors Fit into the Diabetes Treatment Algorithm
9:50am - 10:00am   Q&A
10:00am - 10:30am   Break - Exhibit Hall Open
10:30am - 11:00am   Cardiovascular Risk Reduction and Other Co-Morbidities
11:00am - 11:10am    Q&A
11:10am - 11:45am   Successful Transition to Insulin Replacement Therapy in Type 2 Diabetes
11:45am - 11:55am     Q&A
11:55am - 12:20pm   Diabetes Self-Management and Medical Nutrition Therapy in Type 2 Diabetes
12:20pm - 12:30pm   Q&A
12:30pm - 1:00pm   Case Presentation: Management of Diabetes Applying Science to Practice
1:00pm   Adjourn

 

 *Agenda Subject to Change

 

 

The activity is co-provided/co-sponsored by the American Association of Clinical Endocrinologists and the Postgraduate Institute for Medicine.

 

                

Faculty

Local Program Chair

David Bleich, MD

Chief, Division of Endocrinology, Diabetes, & Metabolism

Associate Professor

UMDNJ-New Jersey Medical School

Newark, NJ

  

Faculty

 Jeffrey Bauman, MD, FACE, ECNU

Chief of Endocrinology, Overlook Medical Center

Summit Medical Group

Berkley Heights, NJ

  

Patricia M. Munz MSN, APN, CDE

Nurse Practitioner

Endocrinology Associates of Central New Jersey

Freehold, NJ

CentraState Healthcare System

Freehold, NJ

 

Maya Raghuwanshi MD, MPH, FACP, FACE

Associate Professor of Medicine

Division of Endocrinology

RBHS-NJMS

Newark, NJ

 

 

Educational Objectives

After participating in the continuing education program, participants will have an improved ability to:

  • Describe the different methods available to diagnose type 2 diabetes.
  • Assess  different different classes of therapeutic agents designed to treat specific diabetic pathophysiologic defects in type 2 diabetes to reach appropriate treatment goals.
  • Explain new strategies for weight management in diabetic patients with obesity.
  • Outline clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific concerns, adverse drug effects and contraindications, and associated comorbidities.
  • Discuss the role and timing of combination therapy in achieving A1C goals.
  • Explain the implications of recent large randomized clinical trials on clinical decision-making.
  • Compare the differences between GLP-1 receptor agonists and DPP-4 inhibitors and alternative antihyperglycemic agents as therapeutic options after metformin failure.
  • Assess the clinical data and different profiles of currently available GLP-1 receptor agonists and DPP-4 inhibitors.
  • Explain the reasons for combining insulin with GLP-1 and DPP4 inhibitors in the treatment of type 2 diabetes.
  • Describe the relationship between major CV risk factors and CVD outcomes.
  • Select therapeutic modalities available to practitioners to improve the CV risk factors.
  • Recognize the implications of recent large trials on clinical decisions guiding choice and targets for blood pressure and lipid abnormalities.
  • Discuss other co-morbid/microvascular conditions seen in patients with type 2 diabetes.
  • Explain the role of statins, ACEi and ARB in the treatment of type 2 diabetes.
  • Select strategies for introduction of insulin to patients who are candidates for this therapy.
  • Describe the current and emerging insulin therapies for the treatment of type 2 diabetes.
  • Describe how to intensify insulin regimen to achieve glycemic targets.
  • Examine available modalities (vials, devices, pumps) for insulin delivery and their use in the outpatient setting.
  • List approaches to incorporate patient education in self-management treatment methods.
  • Develop strategies to involve other healthcare professionals to support the care of patients with type 2 diabetes.
  • Describe the physical activity and nutritional recommendations for patients with type 2 diabetes.
  • Summarize steps to application of the knowledge gained from this activity to practitioner to improve the disease management and outcomes for their patients with type 2 diabetes.
Steering/Program Committee

Chair - George Grunberger, MD, FACP, FACE

Chairman, Grunberger Diabetes Institute

Clinical Professor, Internal Medicine and Molecular Medicine & Genetics

Wayne State University School of Medicine

Bloomfield Hills, MI

 

 Vice Chair - Alan J. Garber, MD, PhD, FACE

Professor Departments of Medicine,

Biochemistry and Molecular Biology and Molecular and Cellular Biology

Baylor College of Medicine

Houston, TX

  

Ex Officio, AACE President - Jeffrey I. Mechanick, MD, FACP, FACE, FACN, ECNU

Clinical Professor of Medicine

Director, Metabolic Support

Division of Endocrinology, Diabetes, and Bone Disease, Mount Sinai School of Medicine

New York, NY

  

Ex Officio, Chair, Council on Education - Pasquale J. Palumbo, MD, MACP, MACE

Professor of Medicine, Mayo Clinic College of Medicine

Scottsdale, AZ

  

David S. H. Bell, MD, MB, FACP, FACE

Adjunct Clinical Professor of Medicine University of Alabama Medical School  

Birmingham, AL

Director, Southside Endocrinology

Mountain Brook, AL 

  

Felice A. Caldarella, MD, FACP, CDE, FACE

Research Director, Diabetes and Endocrine Associates of Hunterdon

Hunterdon Medical Center

Flemington, NJ

   

Chris K. Guerin, MD, FACE, FNLA

Assistant Clinical Professor of Medicine University of California

San Diego, CA

  

Yehuda Handelsman, MD, FACP, FACE, FNLA

Medical Director, Metabolic Institute of America 

Tarzana, CA  

  

Jennifer Hone, MD, FACE  

Director of Diabetes Programs, American Indian Health & Services

Santa Barbara, CA 

  

Daniel L. Hurley, MD, FACE

Assistant Professor of Medicine, Mayo Medical School

Consultant, Division of Endocrinology and Metabolism, Mayo Clinic

Rochester, MN 

  

Bethany A. Jackson, MD

Endocrine Fellow, Medical College of Georgia, Georgia Regents University

Augusta, GA 

  

Armand A. Krikorian, MD, FACE

Internal Medicine Residency Program Director, Advocate Christ Medical Center

Oak Lawn, IL

 

Etie S. Moghissi, MD, FACP, FACE

Clinical Associate Professor, University of California Los Angeles

Los Angeles, CA

 

Fernando Ovalle, MD, FACE

Professor of Medicine, Director, Diabetes and Glycemic Control Programs at UAB

University of Alabama at Birmingham School of Medicine

Birmingham, AL

 

 Jill M. Paulson, MD, ECNU

Rockville Internal Medicine Group, Endocrinology

Rockville, MD 

  

Paul D. Rosenblit, MD, FACE

Clinical Professor, Medicine (Division of Endocrinology, Diabetes, Metabolism)

University California, Irvine (UCI), School of Medicine

Irvine, CA

Co-Director Diabetes Out-Patient Clinic, UCI Medical Center

 Orange, CA

Director, Diabetes/Lipid Management & Research Center

Huntington Beach, CA

  

Cheryl R. Rosenfeld, DO, FACP, FACE

Clinical Assistant Professor of Medicine, NYIT College of Osteopathic Medicine

Old Westbury, NY

Adjunct Clinical Assistant Professor of Medicine, Touro College of Osteopathic Medicine

New York, NY

North Jersey Endocrine Consultants

Denville, NJ

  

Stanley S. Schwartz, MD, FACE

Affiliate Main Line Health System

Emeritus, Clinical Associate Professor of Medicine

University of Pennsylvania

Villanova, PA

  

Elliot Sternthal, MD, FACP, FACE

Assistant Professor of Medicine, Boston University School of Medicine

Boston, MA

 

 Nancy S. Tarlin, MD, FACP, FACE

Co-Director Endocrinology, Elmhurst Hospital

Elmhurst, NY

Assistant Professor Medicine, Mount Sinai School of Medicine

New York, NY

  

Joseph M. Tibaldi, MD, FACP, FACE

Queens Diabetes and Endocrinology Associates

Assistant Clinical Professor of Medicine, Weill Cornell Medical College

New York, NY

   

Jeff Unger, MD

Director, Metabolic Studies, Catalina Research Institute

Director, Unger Primary Care Medical Center

Chino, CA

 

Disclosure

Program Committee Disclosures:

*Dr. George Grunberger reports that he has received speaker honoraria and research support for his role as Investigator from Amylin Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, and Valeritas, Inc.; speaker honoraria from Amarin Corp. and Santarus Inc.; and research support for his role as Investigator from  GlaxoSmithKline plc and Janssen Pharmaceuticals, Inc.  He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Grunberger has an identified conflict of interest, and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Alan J. Garber reports that he has receivedAdvisory Board, consultant, and Speaker’s Bureau’s fees from Merck & Co., Inc., Novo Nordisk A/S, and VIVUS, Inc.; Advisory Board fees from Halozyme Therapeutics; Advisory Board and Speaker’s Bureau fees from Janssen Pharmaceuticals, Inc.; Advisory Board and consultant fees from Takeda Pharmaceuticals North America, Inc.; consultant and Speaker’s Bureau fees from Santarus Inc.; consultant fees from Tethys Bioscience and Viking Therapeutics; and Speaker’s Bureau fees from Eisai Co, Ltd. Dr. Garber has no identified conflicts of interest.

Dr. Jeffrey I, Mechanick reports that he has received Lecture/Program Development honoraria from Abbott Laboratories. Dr. Mechanick has no identified conflicts of interest.

Dr. Pasquale J. Palumbo reports that he does not have any relevant financial relationships with any commercial interests.  Dr. Palumbo has no identified conflicts of interest.

Dr. David S.H. Bell reports that he has received speaker honoraria from AstraZeneca, Boehringer Ingelheim GmbH, Eli Lilly and Company, and Novo Nordisk A/S, and speaker/consultant honoraria from Bristol-Myers Squibb and Takeda Pharmaceuticals North America, Inc.  Dr. Bell has no identified conflicts of interest.

Dr. Felice A. Caldarella reports that he has received speaker honoraria and research compensation from Novo Nordisk A/S, speaker honoraria from Santarus, and research compensation from Boehringer Ingelheim GmbH and Eli Lilly and Company.  Dr. Caldarella has no identified conflicts of interest.

Dr. Chris K. Guerin reports that he has received speaker honoraria from Eli Lilly and Company, Novo Nordisk A/S, and Santarus, Inc. Dr. Guerin has no identified conflicts of interest.

Dr. Yehuda Handelsman reports that he has received research grant support and speaker fees from Boehringer Ingelheim Gmbh and GlaxoSmithKline plc; research grant support from Conjuchem, LLC, Lexicon Pharmaceuticals, Inc., Takeda Pharmaceuticals Northa America, Inc., Tolerx, and Xoma; research grant support and speaker/consultant fees from Daiichi Sankyo Company, Limited and Novo Nordisk A/S; research grant support and consultant fees from Merck& Co. and sanofi-aventis U.S. LLC; consultant fees from Amarin Corp, Gilead, and Halozyme Therapeutics; and consultant/speaker fees from Amylin Pharmaceuticals Inc. Dr. Handelsman has no identified conflicts of interest.

Dr. Jennifer Hone reports that she does not have any relevant financial relationships with any commercial interests. Dr. Hone has no identified conflicts of interest.

Dr. Daniel L. Hurley reports that he does not have any relevant financial relationships with any commercial interests.  Dr. Hurley has no identified conflicts of interest.

Dr. Bethany A. Jackson reports that she does not have any relevant financial relationships with any commercial interests. Dr. Jackson has no identified conflicts of interest.

Dr. Armand A. Krikorian reports that he has received consultant fees from sanofi-aventis U.S. LLC. Dr. Krikorian has no identified conflicts of interest.

Dr. Etie S. Moghissi reports that she has received consultant honoraria from Amylin Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC, speaker honoraria from Boehringer Ingelheim GmbH, and speaker/consultant honoraria from Novo Nordisk A/S. Dr. Moghissi has no identified conflicts of interest.

Dr. Fernando Ovalle reports that he has received consultant/research fees from Bristol-Myers Squibb Company, Jannsen Pharmaceuticals, Inc., Medtronic, Inc., Novo Nordisk A/S, and sanofi-aventis U.S. LLC. Dr. Ovalle has not identified conflicts of interest.

Dr. Jill M. Paulson reports that she does not have any relevant financial relationships with any commercial interests.  Dr. Paulson has no identified conflicts of interest.

Dr. Paul D. Rosenblit reports that he has received speaker/teaching honoraria from Abbott Laboratories, Boehringer Ingelheim Gmbh, and Bristol-Myers Squibb; Advisory Board honoraria from Amarin Corp.; research grant support for his role as Principal Investigator from Andromeda Biotech Ltd., Daiichi Sankyo Company, Limited, and Eisai Co., Ltd.; research grant support for his role as Principal Investigator and speaker/teaching/Advisory Board honoraria from Eli Lilly and Company; research grant support for his role as Principal Investigator and speaker/teacher honoraria from AstraZeneca, GlaxoSmithKline plc,; and research grant support for his role as Principal Investigator and Advisory Board honoraria from Dexcom, Inc. Dr. Rosenblit has no identified conflicts of interest.

Dr. Cheryl R. Rosenfeld reports that she has received speaker honoraria and research grant support for her role as Principal Investigator from Amylin Pharmaceuticals Inc.; speaker honoraria, research grant support for her role as Principal Investigator, and consultant fees from Valeritas, and speaker honoraria from Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH/Eli  Lilly and Company,  and Genzyme. Dr. Rosenfeld has no identified conflicts of interest.

Dr. Stanley S. Schwartz reports that he has received Speaker’s Bureau honoraria from Boehringer Ingelheim GmbH, Novo Nordisk A/S, and Merck & Co., Inc; Advisory Board honoraria from Janssen Pharmaceuticals, Inc. and sanofi-aventis U.S. LLC; and Speaker Bureau and Advisory Board honoraria from AstraZeneca, Bristol Myers Squibb Company/Amylin Pharmaceuticals, Eli Lilly and Company, Santarus Inc. and Takeda Pharmaceuticals North America, Inc. Dr. Schwartz has no identified conflicts of interest.

Dr. Elliot Sternthal reports that he does not have any relevant financial relationships with any commercial interests.  Dr. Sternthal has no identified conflicts of interest.

Dr. Nancy S. Tarlin reports that she has received stock sanofi-aventis U.S. LLC. Dr Tarlin has no identified conflicts of interest.

Dr. Joseph M. Tibaldi reports that he has received speaker honoraria from Daiichi Sankyo Company, Limited, Janssen Pharmaceuticals, Inc., and Merck & Co., Inc., and speaker/consultant honoraria from Novo Nordisk A/S.  Dr. Tibaldi has no identified conflicts of interest.

Dr. Jeff Unger reports that he does not have any relevant financial relationships with any commercial interests.  Dr. Unger has no identified conflicts of interest.

Corporate Support

 

AACE would like to acknowledge the following companies that have provided support for this educational activity.

 

Bristol - Myers Squibb and AstraZeneca LP

 

Boehringer Ingelheim Pharmaceuticals, Inc.,

 which was made possible, in part, through collaboration with Eli Lilly and Company

 

Novo Nordisk Inc.

 

sanofi-aventis U.S.

 

Takeda Pharmaceuticals North America, Inc.

 

*Accurate at time of posting.

 

Physician Credit

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing Credit

This educational activity for 4.5 contact hours is provided by Postgraduate Institute for Medicine.

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485 for 4.5 contact hours.

There is no fee for this educational activity.

A statement of credit will be issued only upon receipt of a completed online activity evalution.

For information about ACPE and ANCC accreditation, please contact Postgraduate Institute for Medicine at (303) 799-1930 or information@pimed.com.

Pharmacist Credit

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 4.8contact hour(s) (0.48 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-13-313-L01-P)

Type of Activity: Application

Upon receipt of a completed online activity evaluation form, transcript information will be made available at www.mycpemonitor.net immediately.

For information about ACPE and ANCC accreditation, please contact Postgraduate Institute for Medicine at (303) 799-1930 or information@pimed.com  

Location

Marriott Newark Liberty International Airport -  Grand Ballroom

1 Hotel Road

Newark, New Jersey 07114

 

 

 

Registration Fees

There is no fee to attend this activity.

 

AACE Membership is not required to attend this program.

 

However, we do ask that you register by clicking the next tab and completing the registration form.

Register
Program Fee
There is no registration fee to attend this meeting. We do request that you pre-register by completing this form. AACE Membership is NOT required to attend this program.
Registration Type
Contact Information
Cancellation Policy
AACE reserves the right to cancel this course based on enrollment or conditions beyond our control. In the case of program cancellation, each pre-registrant will be notified by phone and/or email. AACE is not responsible for any costs incurred due to program cancellation, such as airline or hotel penalties.
E-mail Disclaimer
By entering your email address, you agree that your email address can be used for future correspondence from the American Association of Clinical Endocrinologists. This information would include, but is not limited to certifications, program information and future advertisements.
Finish Registration
A Printed Syllabus will NOT be distributed for this activity.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.